| Name | Title | Contact Details |
|---|
ALERT Life Sciences Computing is a Reston, VA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Tizona Therapeutics, Inc. is a preclinical stage biotechnology company that is developing multiple, innovative immuno-oncology therapies. Tizona Therapeutics, Inc. was founded by MPM Capital and leading scientists from Dana Farber Cancer Institute, the University of Pittsburgh, Johns Hopkins, Memorial Sloan Kettering Cancer Center, and Brigham and Women`s Hospital.
We are a biotechnology leader that discovers, develops and delivers innovative therapies to improve the lives of patients with neurodegenerative diseases, hematologic conditions and autoimmune diseases. Patients worldwide benefit every day from our medicines for multiple sclerosis (MS) and hemophilia. Founded in 1978, we are one of the world’s oldest independent biotechnology companies. Our development pipeline is focused on areas of high unmet medical need, as we pursue new therapies for patients suffering from diseases with few or no treatment options. These include programs for secondary progressive MS, Alzheimer’s Disease, spinal muscular atrophy, lupus and amyotrophic lateral sclerosis (ALS), amongst others. With more than 7,500 people worldwide, we are truly a global organization, headquartered in Cambridge, Massachusetts, which is also home to our research operations. Our international headquarters are based in Zug, Switzerland and we have world-class manufacturing facilities in North Carolina and Denmark. We offer therapies globally through direct affiliate presence in 30 countries and a network of distribution partners in over 50 additional countries.
PaxVax is a privately held, fully integrated vaccine company, based in Redwood City, California, USA. Established in 2007, in response to the global threat of the H5N1 pandemic, our founders set out to develop and commercialize an innovative vaccine technology in a socially responsible manner for global impact. Our founding principles were to enable geographically distributed manufacturing of affordable, self-administered oral vaccines against infectious diseases such as influenza. Since then, we have expanded our capabilities and technologies to address unmet vaccine needs against endemic diseases in developing countries, for travelers to disease-laden areas and in biodefense. Our clinical stage portfolio today includes vaccine candidates for cholera, avian influenza (H5N1), anthrax, and HIV. We are committed to providing both attractive financial returns and social returns, without a significant trade-off between the two. As a double bottom line business, we will measure our financial success in terms of return on equity and we will assess our social returns by access to our vaccines globally, particularly to the poor and otherwise disenfranchised. We strive to develop and deliver vaccines that are affordable and deliverable anywhere in the world regardless of the state of medical infrastructure or supply chains. We utilize investment capital as well as R&D grants and contracts to fund the development of our vaccines. We exploit the inherent synergies in our proprietary oral vaccine technology platform to research and develop multiple vaccine candidates in a timely and capital efficient manner. We strive to make an impact on infectious disease morbidity and mortality throughout the world and on the global vaccine industry through our successes. To date, we have raised more than $75 million (USD) from investors including Ignition Ventures, Ignition Growth and the Wellcome Trust. We are supported by R&D grants and contracts from the U.S. National Institutes of Health (NIH) through both its National Institutes of Allergy and Infectious Diseases (NIAID) and Division of AIDS (DAIDS) as well as the Bill & Melinda Gates Foundation. Our most advanced vaccine is a single dose oral cholera vaccine, which entered final or Phase III clinical trials, and whose study should be completed in 2014. Following this candidate is a vaccine ready for Phase II (Pandemic Influenza), two caccines in current Phase I studies (HIV and anthrax), and multiple candidates in preclinical research (HSV, dengue, malaria). PaxVax is headquartered in Redwood City, California and is incorporated in Delaware. Our laboratory and manufacturing facilities and the majority of our 80 employees are located in San Diego, California.
REGENXBIO is a leading biotechnology company focused on the development, commercialization and licensing of recombinant adeno‐associated virus (AAV) gene therapy. REGENXBIO`s NAV® Technology Platform, a proprietary AAV gene delivery platform, consists of exclusive rights to more than 100 novel AAV vectors, including AAV7, AAV8, AAV9 and AAVrh10. REGENXBIO`s mission is to transform the lives of patients suffering from severe diseases with significant unmet medical need by developing and commercializing in vivo gene therapy products based on REGENXBIO`s NAV Technology Platform. REGENXBIO seeks to accomplish this mission through a combination of internal development efforts and third‐party NAV Technology Platform licensees.